-$0.24 EPS Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
Analysts forecast that Seres Therapeutics, Inc. (NASDAQ:MCRB) will report earnings of ($0.24) per share for the current quarter, Zacks reports. Two analysts have made estimates for Seres Therapeutics’ earnings. The lowest EPS estimate is ($0.25) and the highest is ($0.23). Seres Therapeutics reported earnings per share of ($0.46) in the same quarter last year, which indicates a positive year-over-year growth rate of 47.8%. The firm is scheduled to announce its next earnings report on Thursday, November 9th.
On average, analysts expect that Seres Therapeutics will report full-year earnings of ($2.45) per share for the current fiscal year, with EPS estimates ranging from ($2.78) to ($2.30). For the next financial year, analysts forecast that the firm will post earnings of ($2.79) per share, with EPS estimates ranging from ($3.02) to ($2.49). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Seres Therapeutics.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.59) by $0.10. The company had revenue of $3 million during the quarter, compared to analysts’ expectations of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company’s quarterly revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.70) EPS.
A number of brokerages have commented on MCRB. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Wednesday, August 30th. BidaskClub downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Zacks Investment Research downgraded shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price (up from $15.00) on shares of Seres Therapeutics in a research note on Friday, August 4th. Finally, Canaccord Genuity set a $20.00 target price on shares of Seres Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $17.00.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/09/0-24-eps-expected-for-seres-therapeutics-inc-mcrb-this-quarter.html.
Seres Therapeutics (NASDAQ MCRB) traded up 0.91% on Friday, hitting $14.36. 112,652 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $13.62 and its 200-day moving average price is $11.21. The company’s market cap is $581.75 million. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $15.09.
Institutional investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC purchased a new stake in shares of Seres Therapeutics in the 2nd quarter valued at approximately $114,000. American International Group Inc. raised its stake in shares of Seres Therapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 10,977 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 727 shares during the period. Advisor Group Inc. raised its stake in shares of Seres Therapeutics by 100.7% in the 2nd quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 7,050 shares during the period. State of Wisconsin Investment Board purchased a new stake in shares of Seres Therapeutics in the 2nd quarter valued at approximately $169,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Seres Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 2,410 shares during the period. 74.76% of the stock is currently owned by institutional investors and hedge funds.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.